KOSPIBiotech & Pharma011000

GeneOne Life Science

₩2,670 0.00%2026-11-18 close
Market Cap
₩48.5B
Turnover
₩0
Volume
0 shares
Shares out.
18.2M
PER
—
PBR
2.4×
EPS
-₩2,250
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

CDMO restart tests a balance sheet under pressure

GeneOne Life Science is trying to rebuild revenue through a US CDMO plant restart and a USD 16.9 million DNA supply agreement, but a 191.5% debt ratio and KRW 52.9 billion in controlling-shareholder net losses over the last four quarters keep balance-sheet strength the central question.

  1. 1

    Annual revenue fell from KRW 48.7 billion in 2022 to KRW 23 billion in 2025, and quarterly revenue has declined for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026.

  2. 2

    Subsidiary VGXI disclosed in July 2026 that CDMO production was halted in the first half of 2026 and that no CDMO revenue was recognized in that period.

  3. 3

    Money Today reported on October 26, 2026 that the company restarted its first US plant to fulfill a USD 16.9 million, about KRW 24 billion, mRNA-grade DNA supply contract.

  4. 4

    At the end of 2025, total equity was KRW 40.9 billion, total liabilities KRW 78.3 billion, the debt ratio 191.5%, and operating cash flow was -KRW 16.5 billion.

  5. 5

    A KRW 15 billion third-party share placement with a September 30, 2026 payment date was decided, and in March 2026 the company was flagged for possible designation as an unfaithful-disclosure company over a delayed largest-shareholder change disclosure.

02

Business structure

GeneOne Life Science was founded in 1976 and listed on the KOSPI market in November 1987. Its business is split between a pharmaceutical segment that produces raw materials for clinical-stage DNA vaccines and gene therapies, and a fabric segment that handles apparel interlinings and processed fabrics.

The core pharmaceutical base is its US subsidiary VGXI, which operates a first plant in The Woodlands, Texas and a second plant in Conroe. VGXI disclosed that its CDMO production was fully halted throughout the first half of 2026 and that no CDMO segment revenue was recognized in that period.

The company attributed the halt to asset inspections and production-line adjustments needed to restart the plants, which temporarily suspended finished-product manufacturing. After its lease ended, the first plant was re-leased through January 31, 2037.

On customers, as of June 25, 2026 the company signed a letter of agreement worth USD 16.9 million with one new customer and is preparing a definitive contract, while two existing customers requested additional production quotes.

Looking at recent trends rather than segment weights, revenue depends heavily on whether CDMO production resumes. Against large CDMO players such as Samsung Biologics and Celltrion, which have larger facilities and customer bases, GeneOne is positioned as a smaller production base centered on two US plants. The company is widening its order base through a supply agreement for mRNA-grade DNA.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.1B-₩11.7B−229.7%
2025Q4₩2.7B-₩13.1B−494.9%
2026Q1₩2.6B-₩2.3B−90.8%
2026Q2₩2.1B-₩12.8B−623.0%
2026Q3₩1.8B-₩5.4B−303.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩48.7B-₩40.1B-₩38.1B−82.3%−21.0%22.8%
2023₩40.2B-₩48.4B-₩77.8B−120.3%−69.8%35.4%
2024₩35.7B-₩43B-₩48.5B−120.5%−56.7%76.8%
2025₩23B-₩44B-₩51.9B−191.1%−126.8%191.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a reported annual basis, revenue went from KRW 48.7 billion in 2022 to KRW 40.2 billion in 2023 (down 17.5% year on year), KRW 35.7 billion in 2024 (down 11.2%), and KRW 23 billion in 2025 (down 35.5%), so revenue declined for three consecutive years from 2023 through 2025.

Among 2022 to 2025, 2022 was the largest year and 2025 the smallest. Operating losses were KRW 40.1 billion in 2022, KRW 48.4 billion in 2023, KRW 43 billion in 2024 and KRW 44 billion in 2025, which means four consecutive years of operating losses from 2022 through 2025.

The operating margin moved from -82.3% in 2022 to -120.3% in 2023, -120.5% in 2024 and -191.1% in 2025. Because the operating loss did not shrink much while revenue kept falling, the margin deterioration accelerated.

Net loss attributable to controlling shareholders was KRW 38.1 billion in 2022, KRW 77.8 billion in 2023, KRW 48.5 billion in 2024 and KRW 51.9 billion in 2025.

Net loss including non-controlling interests was KRW 38.2 billion, KRW 77.8 billion, KRW 48.5 billion and KRW 51.9 billion in the same years, so the two figures are close.

Operating cash flow was -KRW 24.1 billion in 2022, -KRW 21.7 billion in 2023, -KRW 16.1 billion in 2024 and -KRW 16.5 billion in 2025, a continued cash outflow.

The debt ratio rose from 22.8% in 2022 to 35.4% in 2023, 76.8% in 2024 and 191.5% in 2025, and all of the KRW 40.9 billion total equity at the end of 2025 belongs to controlling shareholders.

Quarterly revenue fell from KRW 5.08 billion in the third quarter of 2025 to KRW 2.65 billion in the fourth quarter (down 47.8% from the prior quarter), and KRW 1.78 billion in the third quarter of 2026 was down 13.3% from the prior quarter and 64.9% year on year.

Quarterly operating losses were KRW 11.7 billion in the third quarter of 2025, KRW 13.1 billion in the fourth quarter, KRW 2.34 billion in the first quarter of 2026, KRW 12.8 billion in the second quarter and KRW 5.41 billion in the third quarter of 2026, which was narrower than a year earlier.

Net loss attributable to controlling shareholders was KRW 15.4 billion in the third quarter of 2026, smaller than KRW 18.9 billion in the prior quarter but wider than KRW 11.5 billion a year earlier, and the last four quarters total KRW 52.9 billion.

Whether the narrower losses came from revenue recovery or from cost adjustments should be settled by the line items in the next periodic report.

Over the same period, a KRW 5.1 billion convertible bond was paid in on May 7, 2026 and a KRW 15 billion third-party placement was scheduled for September 30, 2026, so outside funding kept covering the losses.

05

Industry analysis

The field GeneOne operates in is CDMO work supplying raw materials for clinical-stage DNA vaccines and gene therapies, so results depend on client clinical progress and pipeline demand.

The fact that the latest supply agreement centers on DNA for mRNA-grade raw material suggests that demand for mRNA-based drug development overlaps with the company's production base.

Read in context, a DNA production base that grew out of pandemic-era vaccine manufacturing appears to be moving toward raw-material demand for other uses.

Against competitors, Samsung Biologics and Celltrion are large players with major production capacity and biopharma manufacturing track records, while GeneOne's facility scale is comparatively small.

Even within the same biopharma sector, where Alteogen and HLB are assessed mainly on technology licensing and platforms, GeneOne's key variables are plant utilization and fulfillment of customer contracts.

The halt in plant operations in the first half of 2026 raised questions about the company's ability to deliver on contracts. The USD 16.9 million agreement and two additional quote requests from existing customers point to demand, but the figures only reach reported results once the definitive contract is signed.

Scarcity of production know-how could support long-term contract wins, yet contract terms and pricing have not been disclosed. The direction of the industry will depend on how steadily client clinical schedules and mRNA-related raw-material orders continue.

06

Outlook

In a first-half 2026 disclosure, the company said that after asset inspections and production-line adjustments to restart its plants, it expects to recognize revenue alongside the start of new projects in the second half.

In a report dated October 26, 2026, a company representative said production could fully resume from early November 2026 once effectiveness testing and staffing are completed. Whether production actually ran after that point does not yet appear in reported results.

The second plant's asset monetization schedule has reportedly been delayed, and the company decided to keep the first plant operating for that reason. Whether the USD 16.9 million agreement becomes a definitive contract is the biggest variable for the next revenue trend.

The company disclosed that its KRW 13 billion operating fund is to be fully used during 2026. The KRW 1.9 billion debt repayment is for a March 2026 borrowing from a savings bank, recorded at a 10% interest rate.

According to the placement disclosure, once payment is completed the largest shareholder is set to change from a shared-growth investment partnership to a private investment partnership holding 25.51%. The 6,224,066 new shares were disclosed as fully subject to a one-year lock-up.

A provisional shareholders' meeting was also convened for October 30, 2026, but its detailed outcomes are not part of the reported results here. The next formal checkpoint is whether revenue recovers and how large the operating loss is in the 2026 annual business report.

07

Valuation

PER
—
PBR
2.4×
ROE
-140.5%
EPS
-₩2,250
BPS
₩1,112
Dividend per share
₩0

PER cannot be calculated because the last four quarters show net losses attributable to controlling shareholders, so earnings-based multiple comparisons do not currently apply. PBR indicates that the share price sits at a premium to book value.

As losses accumulate and total equity shrinks, the same share price produces a higher multiple of net assets. The dividend yield is low and sits below the industry average.

The September 2026 placement was priced at a 10% discount to a reference price, and that reference price was set after the 5-for-1 share consolidation. Until earnings normalize, net-asset-based comparison is the most practical yardstick. The trend in operating losses and the debt ratio therefore remains a precondition for reading the valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Supply agreement and plant restart

Money Today reported the restart of the first US plant on October 26, 2026, and the company cited fulfillment of a USD 16.9 million, about KRW 24 billion, mRNA-grade DNA supply agreement as the reason. According to Digital Today, two existing customers requested additional production quotes. If a definitive contract is signed and production continues, a path opens for CDMO revenue to return.

Narrower operating losses

Quarterly operating losses were KRW 2.34 billion in the first quarter of 2026 and KRW 5.41 billion in the third quarter of 2026, and the third-quarter loss was narrower than a year earlier.

Compared with KRW 13.1 billion in the fourth quarter of 2025 and KRW 12.8 billion in the second quarter of 2026, some quarters show a lower loss level. Whether the narrowing continues will be the first signal of an improving profit structure.

Restructuring and capital raising

Money Today reported that the company has been pursuing restructuring to resolve its large losses. The KRW 15 billion third-party placement in September 2026 was set to fund KRW 13 billion of operating needs and KRW 1.9 billion of debt repayment. If the capital raise eases repayment pressure, room opens for a financial recovery.

09

Bear factors

Revenue decline continues

Revenue has declined for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026, and KRW 1.78 billion in the third quarter of 2026 was down 64.9% year on year. VGXI disclosed that no CDMO revenue was recognized in the first half of 2026. Annual revenue of KRW 23 billion in 2025 was below half of KRW 48.7 billion in 2022.

Weaker financial health

The debt ratio at the end of 2025 was 191.5%, with total liabilities of KRW 78.3 billion exceeding total equity of KRW 40.9 billion. Operating cash flow was negative in every year from 2022 through 2025, at -KRW 16.5 billion in 2025. The company recorded an operating loss of KRW 44 billion in 2025, extending four consecutive years of losses.

Reliance on funding and wider loss quarters

Net loss attributable to controlling shareholders was KRW 15.4 billion in the third quarter of 2026, wider than KRW 11.5 billion a year earlier, and the last four quarters total KRW 52.9 billion. A March 2026 borrowing was recorded at a 10% interest rate. Convertible bond payments and a third-party placement during 2026 show a high reliance on outside funding.

10

Risk factors

Financial and liquidity risk

A KRW 5.1 billion convertible bond was paid in on May 7, 2026, and a KRW 15 billion third-party placement followed in September 2026, so fundraising has recurred. With the debt ratio at 191.5% and operating cash outflows continuing at the end of 2025, the need for further funding could grow.

Because the new shares are under a one-year lock-up, the timing of any increase in tradable supply is also limited.

Production and contract execution risk

CDMO production was fully halted in the first half of 2026, and the reasons included qualification assessment preparation and production-line adjustments. The asset monetization of the second plant has been delayed, so the company is operating the first plant under a re-lease.

If the USD 16.9 million agreement does not become a definitive contract or production starts late, the timing of a revenue recovery could slip.

Governance and disclosure risk

A largest-shareholder change dated February 13, 2026 was disclosed late on March 17, leading to a flagged possible designation as an unfaithful-disclosure company, with a cumulative penalty score of 5 points over the past year.

Under the exchange rules, a penalty score of 10 or more triggers a one-day trading suspension on the designation date. Because the largest shareholder stake is set to shift to a private investment partnership, changes in management direction and governance will need to be checked together.

11

What to watch next

  1. December 31, 2026 (end of fiscal 2026)

    The reference point for checking whether fourth-quarter 2026 revenue breaks the four-quarter decline and whether first-plant operations translate into CDMO revenue.

  2. Ad hoc disclosure after December 2026 (timing undetermined)

    Whether the USD 16.9 million letter of agreement becomes a definitive contract and its final size will determine the next revenue path.

  3. After December 2026 (schedule undetermined)

    Whether the second plant's asset monetization schedule and operating structure are confirmed, which affects fixed-cost burden and production capacity.

  4. March 31, 2027 (annual report filing deadline)

    The point at which fiscal 2026 revenue, operating loss, debt ratio and total equity are formalized in the periodic report.

  5. Mid-October 2027 (scheduled end of one-year lock-up)

    Based on the scheduled listing date of October 16, 2026, the point when the lock-up on new shares ends, a checkpoint for changes in the largest-shareholder stake and tradable supply.

12

Overall view

GeneOne Life Science has seen revenue decline and four consecutive years of operating losses from 2022 through 2025, and in 2026 it is working to create conditions for revenue recovery through a US CDMO plant restart and a USD 16.9 million supply agreement.

The operating loss in the third quarter of 2026 was KRW 5.41 billion, narrower than a year earlier, but the net loss attributable to controlling shareholders was KRW 15.4 billion, wider than a year earlier, so the line items point in different directions.

On the financial side, the debt ratio of 191.5%, total equity of KRW 40.9 billion and continued operating cash outflow at the end of 2025 mean the company depends heavily on outside funding.

Strengths cited include the supply agreement, the plant restart and the narrower operating loss, while weaknesses cited include four consecutive quarters of revenue decline, repeated capital raising through convertible bonds and placements, and a governance disclosure history.

The weight of these factors will shift depending on whether the definitive contract is signed and whether post-restart revenue appears in disclosures. The next formal checkpoint is the fiscal 2026 annual business report, due by March 31, 2027.

The fourth-quarter 2026 revenue trend and the second plant's asset monetization schedule will make the scale of the financial challenge clearer before then.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobkorea.co.kr
  2. digitaltoday.co.kr
  3. digitaltoday.co.kr
  4. kormedi.com
  5. bestwellth.org
  6. digitaltoday.co.kr
  7. mt.co.kr
  8. m.news.nate.com
  9. digitaltoday.co.kr
  10. markets.hankyung.com
  11. markets.hankyung.com
  12. investing.com
  13. pflow.keywordegg.com
  14. littlebproject.com
  15. judal.co.kr
  16. paxnet.co.kr
  17. alpha-lenz.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis